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DOI: http://dx.doi.org/10.1016/j.hemonc.2013.12.002BACKGROUND AND OBJECTIVES: This study aims to examine the possible association of Epstein–Barr virus
(EBV) in Classical Hodgkin lymphoma (cHL) and to shed light on the epidemiology of Hodgkin lymphoma (HL)
in Jordan.
PATIENTS AND METHODS: We examined 100 consecutive cases of HL for the presence of EBV in tumor cells
by immunohistochemistry for latent membrane protein-1 (LMP-1). We collected patient data on age, sex and
histologic subtype. We reviewed the pathological findings in each case and confirmed diagnosis.
RESULTS: Nodular lymphocyte predominant HL was diagnosed in 6% of the cases and these were negative for
EBV LMP-1. Of the 94 cases of cHL, 65% were males, the most common subtype was nodular sclerosis (NS),
representing 70% of the cases, and 45.7% of cHL (43% of all HL) cases were positive for EBV LMP-1. The posi-
tive cases were significantly related to age: 15 years and >51 years (p: 0.009 and 0.014 respectively), male
gender (p: 0.03) and mixed cellularity (MC) subtype (p: <0.0001). In line with other developing countries, there
also appears to be a trend towards a decreasing association of EBV with cHL and a subtype switch from MC to
NS in Jordan.
CONCLUSION: The epidemiology of HL in Jordan and some developing countries is approaching that of devel-
oped countries.HClassical Hodgkin lymphoma (cHL) is knownto be associated with Epstein–Barr virus(EBV) infection.1–21 The frequency of this
linkage varies both between countries as well as within
the same country, and is presumed to be related to the
socioeconomic status of the population. It also varies
within each histologic subtype of cHL, gender and age
at the time of diagnosis. The association between cHL
and EBV is more likely to be found in developing
countries than in more developed ones,1,22 and is re-
ported to decrease as the socioeconomic status of the
population improves and approaches that of devel-
oped countries.20–22
Jordan is a developing country that is gradually
adopting a western life style. This trend is reﬂected
in general health issues, evident from the increasing
prevalence of obesity, diabetes and colon cancer.23
Previous studies from Jordan24–26 and other Middle
Eastern (ME) countries12,13,16–18,28,29,30 have re-
ported a varying range of EBV association with HL,ematol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.coranging from 28% to 47% 24–26 in Jordan and up to
87% in other ME countries such as Iran.26
The aim of this study is to shed further light on
the more recent epidemiology of Hodgkin’s lym-
phoma and its association with EBV infection in
Jordan.MATERIALS AND METHODS
One hundred consecutive cases of HL diagnosed be-
tween 2006 and 2008, with available parafﬁn blocks
were retrieved from the archives of the pathology
department at King Hussein Cancer Center
(KHCC). The original slides, inclusive of immunohis-
tochemical studies, were independently reviewed by
two senior pathologists to conﬁrm diagnosis and his-
tological subtype in each of the cases. Any discrepancy
as to subtype was resolved by a consensus meeting.
Immunostaining for Epstein–Barr virus latent
membrane protein-1 (LMP-1) (CS1-4, Cell Marquem 85
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Corp. Hot Springs, AR) was performed on all the
cases using an automated platform (Ventana Bench-
Mark, Ventana Medical Systems Inc., Tucson, AR),
and employing standard protocols according to the
manufacturer’s recommendations. Immunostaining
was considered positive if typical cytoplasmic and
membranous staining was observed in Reed-Stern-
berg/Hodgkin cells regardless of the number of posi-
tively stained cells. Appropriate positive and negative
controls were used for every case. The interpretation
of immunostaining was conducted independently by
two senior physicians. A consensus was reached on
all cases.
Statistical analysis was performed using Chi square
test or Fisher’s exact test. A signiﬁcance criterion of
p  0.05 was used in the analysis. All analysis was
performed using SAS version 9.1 (SAS Institute
Inc, Cary, NC).RESULTS
Classic Hodgkin lymphoma represented 94 (94%) of
the 100 consecutive cases studied while 6 (6%) were
diagnosed as nodular lymphocyte predominant
Hodgkin lymphoma (NLPHL). The age and sex of
the patients stratiﬁed by the histological subtype are
presented in Table 1.
There were 67 (67%) males and 33 (33%) females.
NLPHL
Of the 100 cases there were six cases of NLPHL
(Table 1). All patients were males and their ages ran-
ged from ﬁve to 42 years (median age, 24 years). All
cases were negative for EBV LMP-1 immunostaining.
cHL
There were 94 patients with cHL out of the 100 HL
cases studied. Of these, 63 (65%) were males and 33
(35%) were females (age range 3–73 years; median
age, 24 years). The highest incidence was in the young
adult group (16–50 years), constituting 66 (70%) of
the 94 cases, followed by the 19 cases (20%) in the
childhood group (15 years). 16 (84%) of these 19
children were boys.
Nodular sclerosis (NS) subtype was the most com-
mon subtype in all age groups ranging from 58% in
the childhood group to 74% in the young adult group,
and representing 70% of the entire group. Mixed cel-
lularity (MC) was the second most common subtype
and represented 28% of the entire group. In contrast
to NS, MC was rarely encountered in females, with
only 19% of the cases occurring in females compared
to 42% of the cases in NS subtype. There were twoHemapatients with lymphocyte rich subtype and no cases
of lymphocyte depletion HL.
Tumor cells were positive for LMP-1 in 43 cases
(45.7%) of all cHL cases. The clinicopathologic fea-
tures of the positive and negative cases are shown
and compared in Table 2.
The EBV positive cases were more frequently
encountered in the childhood (15 years) and elderly
(>51 years) age groups, 68% and 78% positivity,
respectively, in contrast to 35% in the young adult
group (16–50 years); and this was statistically signif-
icant (Table 2). There were also more positive cases
amongst males (54%) than females (30%), which
was also statistically signiﬁcant (p: 0.03). The histo-
logic subtype was also a factor strongly linked to pos-
itivity, with 81% in MC vs. 30% in NS (p: <0.0001).
Childhood cHL had 55% positivity in NS and 86% in
MC.
All positive childhood cases were males except for
a single case in a female.DISCUSSION
This study shows that of all HL cases in Jordan the
proportion of cHL is 94% and 6% in NLPHL. The
latter is in agreement with the WHO Handbook27
ﬁgure of 5%, and close to the same percentage as in
the previous study from Jordan published in 2004
which showed a 3% rate,24 and to the 6.7% recorded
in a study from Kuwait12 in 2003. This is, however, in
sharp contrast to the 18% incidence data from Cairo,
Egypt, published quite recently by Audouin et al.22
and the 10% and 12% reported by Al-Salam from
UAE18 and Akhtar30 from Saudi Arabia, respectively.
The populations in Jordan, Egypt, UAE and Saudi
Arabia are essentially the same, and the epidemiology
of cHL is similar in those countries. There is no
apparent reason for this discrepancy. However, the
small sample size used in the studies could be a cause
for speculation.
Three studies have examined the association of HL
with EBV infection in Jordan.24–26 In two of the stud-
ies, the number of patients was low, 16 and 28 respec-
tively,26,25 and there was a modest 64 patients in the
third.24 The proportion of EBV-associated cases was
28% in one study25 but was 47% and 50% in the other
two. The latter two values are similar to our ﬁndings
(43%) for all HL patients. These ﬁgures appear to
be more accurate than the 28% reported in 2004,25
and are comparable to those of other ME countries,
where the association ranges from 47% to 72%.28
The discrepancy in the rate of association could be
related to low numbers of patients and pediatric casestol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.com
Table 1. Correlation of age and sex with histological subtype of HL in Jordan.
Classification of Hodgkin lymphoma Age groups (years) Sex
15 16–50 51 Male Female
Classic Hodgkin Lymphoma (cHL): 94 cases (94%) 61 (65%) 33 (35%)
Nodular sclerosis: 66 cases (70%) 11 49 6 38 28
Mixed cellularity: 26 cases (28%) 7 16 3 21 5
Lymphoid depletion: 0 case 0 0 0 0 0
Lymphocyte rich: 2 cases (2 %) 1 1 0 2 0
Nodular Lymphocyte predominant HL: 6 cases (6%) 2 4 0 6 0
Total: 100 cases 21 (21%) 70 (70%) 9 (9%) 67 (67%) 33 (33%)
Table 2. Comparison of LMP-1 positive vs. LMP-1 negative cases.
Number of patients LMP-1 positive LMP-1 negative P-value
Age group <15 19 13 6 0.0091*
16–50 66 23 43 –
>51 9 7 2 0.014*
Gender Male 61 33 28 0.03
Female 33 10 23
Subtype NS 66 20 46 <0.0001
MC 26 21 5
*Compared to the 16–50 age group.
EPSTEIN–BARR VIRUS AND HODGKIN LYMPHOMA IN JORDAN original research reportincluded in showing only 28% association rate where
only 10% of patients were below 15 years as opposed
to 21% in our study.
Audouin et al.22 reviewed the incidence of EBV
association with HL from different countries world-
wide, grouping the countries by geographical regions.
It is of interest to note that this association varies
from one country to another and differs according
to the year of publication in the same country. One
way to look at the varying data in their report would
be to calculate the average association of HL with
EBV in each region of the world to reach an approx-
imate ﬁgure. The world can then be classiﬁed into
high association regions, such as East Africa with an
average rate of 80%, intermediate association areas
as in the ME with an average of 58%, South and Cen-
tral America with 57%, and Asia with 61%, and low
association countries like USA and Europe with
43% and 46% respectively.Hematol Oncol Stem Cell Ther 7(2) Second Quarter 2014 hemoncstem.edmgr.coThe 43% association found in our study is closer
to that of developed countries, perhaps reﬂecting so-
cio-economic improvement in Jordan. Furthermore,
the 43% association rate we report here is slightly low-
er than that reported by Almasri et al.24 on a cohort
diagnosed between 1996 and 1999, almost a decade
before the diagnosis time period of our cohort, be-
tween 2006 and 2008.
An interesting revelation between these two stud-
ies in Jordan is that the histologic subtype pattern
in cHL has switched from a predominantly mixed cel-
lularity subtype, representing 53% of all HL cases in
the earlier study24 to a predominantly NS subtype,
now representing 70% of all cases with MC represent-
ing only 28% of all cases. The latter includes the pedi-
atric age group patients in the current study. This
subtype switch is similar to that reported by Chang
et al.19 who also showed a decrease in the number
of MC and an increase in the number of NS, withm 87
88
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a more dramatic decrease in the number of EBV-asso-
ciated positive cases over the years. These ﬁgures are
also similar to the ﬁndings in the United Arab Emir-
ates (UAE), Egypt, Saudi Arabia and Northern Chi-
na where NS was reported to be the most common
subtype.18,22,29–31 In Saudi Arabia, they also noticed
a continuous increase over time in NS subtype while
other subtypes decreased.29
The epidemiology of HL is extensively studied.
Three patterns of the disease were described based
on the industrialization level of the population.4,32
In Jordan, the epidemiological pattern seen is closer
to that of developed countries than of transitional
economies in that the great majority of cases were
in the young adult group, and with NS as the most
common subtype.
Our pediatric cases showed an overall EBV posi-
tivity of 68%, with 86% positivity in MC and 55%
in NS subtype, with almost all positive cases occur-
ring in males. Our ﬁndings are similar to those re-
corded in South Africa35 UAE18,34 and
Argentina,35,36 and in sharp contrast to all other
developing countries, which report a rate of 90–
100% for EBV association in children with cHL.37–41
Our ﬁndings are again not consistent with an ear-
lier 1996 study result on childhood HL in Jordan,
which reported a 50% association of EBV.26 This
study did not utilize immunostaining to conﬁrm
HL diagnosis, and it is possible that some of the cases
were not HL.
Pediatric HL with EBV association can also be
sub-classiﬁed by regional averages. Regions are di-Hemavided into high childhood EBV association (Africa,
South America and Asia), intermediate rates (ME),
and low association (USA and Europe).22 The nota-
ble exception is Argentina35,36 and urban areas of Bra-
zil42 where the association is similar to that of ME
countries. It is possible that this intermediate associ-
ation of Argentina, urban areas of Brazil, and ME
countries reﬂects an improvement in socioeconomic
status in recent years. The epidemiology of HL in Jor-
dan and some ME countries is approaching that of
developed countries.
Still unresolved is the etiology/pathogenesis of
non-EBV associated cHL and NLPHL. Theories1,3
have been proposed for a possible etiology but until
now none has been veriﬁed. Recent studies have
shown that there are numerous and heterogeneous ge-
netic lesions in HL with frequent transforming events
in members of the NF-jB and JAK/STAT signaling
pathways, suggesting that these have a critical role in
HL development. Interestingly, it was recently shown
that EBV infection has little speciﬁc inﬂuence on gene
expression of HRS cells.43 However, it seems that the
etiology of non-EBV associated cHL and NLPHL is
less likely to be related to an infectious etiology, as it
appears these are associated with improving socioeco-
nomic status, though this is yet to be conﬁrmed.CONFLICT OF INTEREST STATEMENT
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